Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis
about
Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotypePutting together the psoriasis puzzle: an update on developing targeted therapiesMeta-analysis of shared genetic architecture across ten pediatric autoimmune diseasesTacrolimus ointment improves psoriasis in a microplaque assay.A global gene expression analysis of the peripheral blood mononuclear cells reveals the gene expression signature in psoriasis.Topical tacrolimus in dermatology.Progress in understanding the immunopathogenesis of psoriasisMetabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases.FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.FK 506 and autoimmune disease: perspective and prospects.Tacrolimus: a review of its use for the management of dermatoses.Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study.Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506).Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology.FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension.Pimecrolimus -- an anti-inflammatory drug targeting the skin.Novel pharmacological approaches in the treatment of psoriasis.Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research.Systemic ciclosporin and tacrolimus in dermatology.Tacrolimus: approved and unapproved dermatologic indications/uses-physician's sequential literature survey: part II.Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways.IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.Therapeutic progress. II: Treatment of psoriasis.FK-506--a novel immunosuppressant.Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis.Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report.Tacrolimus for the management of psoriasis: clinical utility and place in therapy.
P2860
Q24561448-D3B3DC9C-91AF-4ABA-AD65-17325BAB12ADQ27026785-2115BFB1-DC29-4871-B313-BFDDB219BCFAQ28394008-777D95B8-6753-402D-A822-89E7850EF50DQ30741048-19D98AF9-238B-4192-AAC4-AE5C5F86E499Q33816921-BC719BBB-276D-4B98-9A8D-FD37BA0389ECQ33938145-C38C0C06-5843-49EB-BE35-89E1680C6DDFQ34215381-F7D0CA80-0FE6-467B-A37E-103C93919E17Q34250881-B697EB78-AD62-4638-80BB-65809FB3F1B8Q34251607-D63E443A-8AF5-467F-9B14-D6DDBA20E7B5Q34257329-A2B25F2A-D5E1-490B-8CD2-E9BF95205CAAQ34668921-C5A9F895-5280-4F84-8858-AD53BD0CBC47Q34886573-79C48B15-BE42-4132-B022-0B889F4670A9Q34966232-AA1E5EBA-1B32-4C17-AD80-41E964C76C4FQ35015840-36DA4958-93D3-4CE4-8A6C-F40A70DFF358Q35024911-E0733FDA-0E5D-4F35-A372-1F49A5299795Q35961095-5FB2FFB7-EAC7-4795-A48A-FE3770B2E463Q36008673-9F17D49A-C082-4AB7-BB43-0066CFA31AEAQ36917184-8D87D029-C57B-448A-838E-A46F76157F9CQ36986032-1F407B72-417A-46BA-BFF9-501AF1BC853DQ37104570-0E7B5C76-52A6-4127-B0AF-3468EBD65806Q37298535-85B39011-0120-4BD7-BD33-4EE68BA3C154Q37378185-F84859D9-2633-4AAA-A9DF-CB4B4E3A12FFQ40395262-61848CF1-2B77-44B2-B928-E4F600C6A654Q40489670-525C7FA9-3699-452C-B3F9-C31D47101C9CQ41884115-64B4D2CC-EEA9-41C7-8862-65DA465CAE28Q44902754-DC57F9E5-4F4C-4E36-92CC-86F05F3DC4E7Q55023453-512B43A6-6234-433F-B8AE-D75FE57BB88F
P2860
Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis
@ast
Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis
@en
type
label
Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis
@ast
Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis
@en
prefLabel
Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis
@ast
Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis
@en
P2093
P2860
P1433
P1476
Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis
@en
P2093
B V Jegasothy
C D Ackerman
K Abu-Elmagd
P2860
P304
P356
10.1001/ARCHDERM.128.6.781
P577
1992-06-01T00:00:00Z